TOVX stock forecast
Our latest prediction for Theriva Biologics Inc's stock price was made on the Jan. 4, 2023 when the stock price was at 0.57$.
In the short term (2weeks), TOVX's stock price should underperform the market by -2.53%. During that period the price should oscillate between -13.91% and +10.93%.
In the medium term (3months), TOVX's stock price should underperform the market by -7.85%. During that period the price should oscillate between -31.01% and +31.24%.Get email alerts
Create a solid portfolio with TOVX
About Theriva Biologics Inc
Synthetic Biologics, Inc. is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company's lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -0.71$ per share.
The book value per share is 3.67$
Three months stock forecastJan. 4, 2023
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|